Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Dermatologic Oncology

Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab

Cancer Chemotherapy and Pharmacology | Mar 12, 2018 Dermatologic Oncology

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis

The Lancet Oncology | Feb 16, 2018 Dermatologic Oncology

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab vs ipilimumab alone in patients with advanced, unresectable melanoma

Journal of Clinical Oncology | Feb 15, 2018 Dermatologic Oncology

High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma

Histopathology | Feb 14, 2018 Dermatologic Oncology

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: A US Food and Drug Administration pooled analysis

The Lancet Oncology | Feb 06, 2018 Dermatologic Oncology

Overall survival in patients with advanced melanoma who received nivolumab vs investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial

Journal of Clinical Oncology | Feb 02, 2018 Dermatologic Oncology

HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors

Journal of Dermatological Science | Feb 02, 2018 Dermatologic Oncology

T-cell papulosis associated with B-cell malignancy: A distinctive clinicopathologic entity

Journal of the European Academy of Dermatology and Venereology | Jan 28, 2018 Dermatologic Oncology

Neoadjuvant plus adjuvant dabrafenib and trametinib vs standard of care in patients with high-risk, surgically resectable melanoma: A single-centre, open-label, randomised, phase 2 trial

The Lancet Oncology | Jan 24, 2018 Dermatologic Oncology

Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma

JAMA Oncology | Jan 17, 2018 Dermatologic Oncology

« Prev 1 … 47 48 49 50 51 … 57 Next »

Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab vs ipilimumab alone in patients with advanced, unresectable melanoma

High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: A US Food and Drug Administration pooled analysis

Overall survival in patients with advanced melanoma who received nivolumab vs investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial

HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors

T-cell papulosis associated with B-cell malignancy: A distinctive clinicopathologic entity

Neoadjuvant plus adjuvant dabrafenib and trametinib vs standard of care in patients with high-risk, surgically resectable melanoma: A single-centre, open-label, randomised, phase 2 trial

Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Awareness for COPD: MCQ challenge

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab vs ipilimumab alone in patients with advanced, unresectable melanoma

High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: A US Food and Drug Administration pooled analysis

Overall survival in patients with advanced melanoma who received nivolumab vs investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial

HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors

T-cell papulosis associated with B-cell malignancy: A distinctive clinicopathologic entity

Neoadjuvant plus adjuvant dabrafenib and trametinib vs standard of care in patients with high-risk, surgically resectable melanoma: A single-centre, open-label, randomised, phase 2 trial

Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

These Popular Snacks Linked a Decline in Mental Health

Awareness for COPD: MCQ challenge

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

Select Specialty

Select Topic